Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Small business labeling guidance

This article was originally published in The Tan Sheet

Executive Summary

Draft guidance titled "1Labeling OTC Human Drug Products (Small Entity Compliance)", published in the Federal Register Dec. 9, is an effort "to help small businesses better understand the new over-the-counter labeling requirements and to prepare new labeling within the prescribed implementation compliance dates," FDA says. This is the third guidance the agency has issued on "Drug Facts" labeling, following one on ANDA labeling and another on column formats (2"The Tan Sheet" Oct. 21, 2002, p. 5). The draft "describes how to list those inactive ingredients that are different when a finished OTC drug product is obtained from multiple suppliers," the agency notes...
Advertisement

Related Content

Final label guidance issued
FDA OTC Labeling Guidance Allows Flexible Approach To Template Use
FDA OTC Labeling Guidance Allows Flexible Approach To Template Use

Topics

Advertisement
UsernamePublicRestriction

Register

PS097631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel